Overview
iRhythm Technologies, Inc., headquartered in the United States, operates primarily within the healthcare technology sector. The company specializes in developing and marketing innovative cardiac monitoring solutions. A notable product from iRhythm is the Zio Patch, a wearable device designed to detect and analyze irregular heart rhythms over an extended period. This device aids in diagnosing conditions such as atrial fibrillation, thereby facilitating more effective clinical decisions. iRhythm Technologies focuses on integrating artificial intelligence to enhance the accuracy and efficiency of its cardiac monitoring solutions. Their commitment to advancing non-invasive cardiac monitoring has positioned them as pioneers in the digital healthcare space, contributing to both improved patient outcomes and healthcare cost efficiencies.
Basic Stats
The share price of iRhythm Technologies, Inc. as of September 5, 2025 is $181.06 / share. This is an increase of 6.52% from the prior week. The market cap (or net worth) of iRhythm Technologies, Inc. as of September 5, 2025 is $5,812.93 MM.
The Factor Analysis chart (below right) shows a view of iRhythm Technologies, Inc. from a variety of lenses. Each factor shows how well the company ranks against all other companies in the Fintel global investing universe. Factor scores range from zero to 100, with 100 being most desirable, and 50 being average.
For example, a company with a Value Score of 100 would be the most undervalued company in our database. A company with a Value Score of zero would be the most overvalued.
| Market Cap | 5,812.93 MM |
| EV | 6,151.83 MM |
| Shares Out. | 32.10 MM |
| Earnings Date | |
| EPS (TTM) | -2.88 |
| Dividend Yield | |
| Ex-Dividend Date | |
| Borrow Rate | 0.25 |
| Short Shares Avail. | 0.30 MM |
| Short Interest | 2.65 MM |
| Short Float | 8.36 % |
| Days to Cover | 6.84 days |
| Risk Free Rate | 4.17 % |
| Price Change (1 yr) | 177.66 % |
| Volatility (1 yr) | 0.55 |
| Beta | 1.03 |
| Sharpe Ratio (1 yr) | 3.16 |
| Sortino Ratio (1 yr) | 7.59 |
| PE Ratio | -62.89 |
| Price/Book | 56.08 |
| Price/TBV | 56.55 |
| Book/Market | 0.02 |
| EBIT/EV | -0.01 |
| EBIT(3yr avg)/EV | -0.02 |
| ROA | -0.10 |
| ROE | -0.93 |
| ROIC | -0.11 |
| CROIC | -0.29 |
| OCROIC | 0.08 |
| Implied Volatility | 37.49 % |
| Put/Call OI Ratio | 1.62 |
Factor Scores range from 0 to 100, with 100 being most desirable. Larger circles are better. In situations where we have no data (e.g. no insider trades), we plot the score at 50 to avoid penalizing companies. However, a company that does not pay dividends will get a Dividend Score of Zero. Additionally, we inverted volatility to create a "stability" metric which is better when higher.
Price Target
The average one-year price target for iRhythm Technologies, Inc. is $183.97. The forecasts range from a low of $159.58 to a high of $204.75. A stock’s price target is the price at which analysts consider it fairly valued with respect to its projected earnings and historical earnings. Analysts typically set price targets that correspond to their buy or sell recommendations.
Update Frequency: Monthly
Stock Upgrades/Downgrades
This card shows analyst upgrades/downgrades for iRhythm Technologies, Inc.. An analyst rating is a classification that gives investors a sense of analyst sentiment about the direction and performance of an equity - usually a stock - over a period of time, typically 12 months.
The standard analyst ratings are generally as follows:
- Buy/Overweight/Outperform - Any of these ratings conveys an analyst’s belief that the stock is likely to outperform a market index (e.g. the S&P 500).
- Hold/Equal-Weight/Market Perform - Any of these ratings conveys an analyst’s belief that the stock is likely to perform in line with a market index.
- Sell/Underweight/Underperform - Any of these ratings suggest that an analyst believes the stock is likely to underperform a market index.
When an analyst upgrades a stock, they are signaling that the company’s fundamentals are being undervalued by investors. It could also mean they believe the market is underestimating the company’s potential. The opposite is true when a stock receives a downgrade.
The average rating of each individual analyst’s rating is the consensus rating for a stock. This gives investors a broader sense of the overall sentiment for that stock.
| Date | Analyst | Prior | Latest Recommendation |
Action |
|---|---|---|---|---|
| 2023-01-06 | Morgan Stanley | Overweight | Maintains | |
| 2022-12-20 | Truist Securities | Buy | Maintains | |
| 2022-12-12 | Citigroup | Neutral | Maintains | |
| 2022-11-02 | Needham | Buy | Maintains | |
| 2022-11-02 | Citigroup | Neutral | Maintains | |
| 2022-10-17 | Truist Securities | Buy | Maintains | |
| 2022-10-11 | Morgan Stanley | Overweight | Maintains | |
| 2022-09-22 | Morgan Stanley | Overweight | Maintains | |
| 2022-09-22 | JP Morgan | Overweight | Maintains | |
| 2022-09-02 | Canaccord Genuity | Buy | Maintains | |
| 2022-08-05 | BTIG | Buy | Maintains | |
| 2022-06-24 | BTIG | Buy | Maintains | |
| 2022-06-22 | JP Morgan | Overweight | Maintains | |
| 2022-06-16 | Truist Securities | Buy | Maintains | |
| 2022-06-09 | Citigroup | Buy | Neutral | Downgrade |
| 2022-05-06 | Needham | Buy | Maintains | |
| 2022-05-06 | Morgan Stanley | Overweight | Maintains | |
| 2022-05-06 | Citigroup | Buy | Maintains | |
| 2022-04-06 | Wolfe Research | Underperform | Initiate | |
| 2022-04-04 | JP Morgan | Overweight | Maintains | |
| 2022-02-24 | Needham | Hold | Buy | Upgrade |
| 2022-02-24 | Morgan Stanley | Overweight | Maintains | |
| 2022-01-27 | JP Morgan | Overweight | Maintains | |
| 2022-01-18 | Morgan Stanley | Equal-Weight | Overweight | Upgrade |
| 2022-01-14 | Citigroup | Buy | Maintains | |
| 2022-01-14 | Canaccord Genuity | Buy | Maintains | |
| 2022-01-12 | BTIG | Neutral | Buy | Upgrade |
| 2022-01-11 | Oppenheimer | Perform | Outperform | Upgrade |
| 2022-01-07 | Morgan Stanley | Equal-Weight | Maintains | |
| 2021-12-17 | JP Morgan | Neutral | Overweight | Upgrade |
| 2021-12-15 | Citigroup | Neutral | Buy | Upgrade |
| 2021-11-08 | Morgan Stanley | Equal-Weight | Maintains | |
| 2021-06-03 | Morgan Stanley | Equal-Weight | Maintains | |
| 2021-06-02 | Citigroup | Buy | Neutral | Downgrade |
| 2021-04-14 | Morgan Stanley | Overweight | Equal-Weight | Downgrade |
| 2021-04-13 | Truist Securities | Buy | Maintains | |
| 2021-04-13 | BTIG | Buy | Neutral | Downgrade |
| 2021-04-12 | Baird | Neutral | Maintains | |
| 2021-03-01 | Citigroup | Buy | Maintains | |
| 2021-02-26 | Colliers Securities | Buy | Neutral | Downgrade |
| 2021-02-04 | BTIG | Buy | Maintains | |
| 2021-02-01 | Truist Securities | Buy | Maintains | |
| 2021-01-25 | Morgan Stanley | Overweight | Maintains | |
| 2020-12-15 | Morgan Stanley | Overweight | Maintains | |
| 2020-12-03 | Morgan Stanley | Overweight | Maintains | |
| 2020-11-06 | Morgan Stanley | Overweight | Maintains | |
| 2020-11-06 | Canaccord Genuity | Buy | Maintains | |
| 2020-09-11 | Needham | Hold | Initiate | |
| 2020-09-02 | Baird | Neutral | Initiate | |
| 2020-08-26 | Canaccord Genuity | Buy | Maintains | |
| 2020-08-05 | Oppenheimer | Perform | Outperform | Upgrade |
| 2020-05-08 | SunTrust Robinson Humphrey | Buy | Maintains | |
| 2020-05-08 | Morgan Stanley | Overweight | Maintains | |
| 2020-05-08 | JP Morgan | Overweight | Maintains | |
| 2020-04-13 | Canaccord Genuity | Buy | Maintains | |
| 2020-03-27 | Morgan Stanley | Overweight | Maintains | |
| 2020-03-27 | Citigroup | Buy | Maintains | |
| 2020-03-05 | Citigroup | Buy | Initiate | |
| 2020-02-28 | Canaccord Genuity | Buy | Maintains | |
| 2020-01-08 | SunTrust Robinson Humphrey | Buy | Initiate | |
| 2019-12-17 | Morgan Stanley | Overweight | Maintains | |
| 2019-04-03 | BTIG Research | Neutral | Buy | Upgrade |
| 2019-02-20 | Chardan Capital | Buy | Neutral | Downgrade |
| 2019-02-13 | Morgan Stanley | Overweight | Overweight | Maintains |
| 2019-02-13 | Canaccord Genuity | Buy | Buy | Maintains |
| 2019-02-13 | BMO Capital | Outperform | Outperform | Maintains |
| 2019-01-11 | Canaccord Genuity | Buy | Buy | Maintains |
| 2018-10-11 | Morgan Stanley | Overweight | Overweight | Maintains |
| 2018-09-13 | Canaccord Genuity | Buy | Buy | Maintains |
| 2018-09-06 | Chardan Capital | Buy | Initiate | |
| 2018-08-02 | Morgan Stanley | Overweight | Overweight | Maintains |
| 2018-08-02 | BMO Capital | Outperform | Outperform | Maintains |
| 2018-06-04 | Morgan Stanley | Overweight | Overweight | Maintains |
| 2018-03-12 | Canaccord Genuity | Buy | Buy | Maintains |
| 2018-03-06 | BMO Capital | Outperform | Initiate | |
| 2018-02-15 | JP Morgan | Overweight | Overweight | Maintains |
| 2017-12-04 | RBC Capital | Outperform | Initiate | |
| 2017-11-03 | Morgan Stanley | Overweight | Maintains | |
| 2017-11-02 | Canaccord Genuity | Buy | Maintains | |
| 2017-09-22 | Canaccord Genuity | Buy | Maintains | |
| 2016-12-06 | BTIG Research | Buy | Neutral | Downgrade |
| 2016-11-14 | Morgan Stanley | Overweight | Initiate | |
| 2016-11-14 | JP Morgan | Overweight | Initiate | |
| 2016-11-14 | Canaccord Genuity | Buy | Initiate | |
| 2016-11-14 | BTIG Research | Buy | Initiate | |
| 2023-02-07 | Wells Fargo | Overweight | Initiate | |
| 2023-02-24 | Canaccord Genuity | Buy | Maintains | |
| 2023-02-24 | Morgan Stanley | Overweight | Maintains | |
| 2023-02-24 | Needham | Buy | Maintains | |
| 2023-04-03 | Citigroup | Neutral | Maintains | |
| 2023-04-17 | BTIG | Buy | Maintains | |
| 2023-04-17 | Truist Securities | Buy | Maintains | |
| 2023-05-05 | Truist Securities | Buy | Maintains | |
| 2023-05-05 | Citigroup | Neutral | Maintains | |
| 2023-05-05 | Needham | Buy | Maintains | |
| 2023-05-05 | Morgan Stanley | Overweight | Maintains | |
| 2023-06-07 | Citigroup | Neutral | Neutral | Maintains |
| 2023-06-07 | Canaccord Genuity | Buy | Buy | Reiterate |
| 2023-06-07 | Oppenheimer | Outperform | Outperform | Maintains |
| 2023-06-08 | BTIG | Buy | Maintains | |
| 2023-10-11 | Morgan Stanley | Overweight | Overweight | Maintains |
| 2023-08-04 | Needham | Buy | Buy | Maintains |
| 2023-07-19 | Baird | Outperform | Initiate | |
| 2023-11-03 | Needham | Buy | Buy | Maintains |
| 2023-08-04 | Morgan Stanley | Overweight | Overweight | Reiterate |
| 2023-08-28 | Canaccord Genuity | Buy | Buy | Maintains |
| 2023-12-22 | Truist Securities | Buy | Buy | Maintains |
| 2023-08-07 | Truist Securities | Buy | Buy | Maintains |
| 2024-02-23 | Needham | Buy | Buy | Maintains |
| 2023-07-11 | Morgan Stanley | Overweight | Overweight | Reiterate |
| 2023-12-11 | Citigroup | Neutral | Buy | Upgrade |
| 2023-12-12 | Truist Securities | Buy | Buy | Maintains |
| 2024-05-03 | Needham | Buy | Buy | Maintains |
| 2024-02-23 | JP Morgan | Overweight | Overweight | Maintains |
| 2024-02-23 | Canaccord Genuity | Buy | Buy | Maintains |
| 2024-05-03 | Canaccord Genuity | Buy | Buy | Maintains |
| 2024-01-08 | Needham | Buy | Buy | Maintains |
| 2024-06-20 | Wolfe Research | Peer Perform | Outperform | Upgrade |
| 2024-07-15 | Morgan Stanley | Overweight | Overweight | Maintains |
| 2024-07-16 | Truist Securities | Buy | Buy | Maintains |
| 2024-08-02 | Truist Securities | Buy | Buy | Reiterate |
| 2024-08-02 | Needham | Buy | Buy | Maintains |
| 2025-08-01 | Canaccord Genuity | Buy | Buy | Maintains |
| 2025-08-01 | JP Morgan | Overweight | Overweight | Maintains |
| 2025-08-01 | Wells Fargo | Overweight | Overweight | Maintains |
| 2024-09-25 | Canaccord Genuity | Buy | Buy | Maintains |
| 2024-11-01 | Baird | Outperform | Outperform | Maintains |
| 2024-12-18 | Truist Securities | Buy | Buy | Maintains |
| 2024-10-22 | Truist Securities | Buy | Buy | Maintains |
| 2024-08-02 | JP Morgan | Overweight | Overweight | Maintains |
| 2024-08-02 | Baird | Outperform | Outperform | Maintains |
| 2024-08-02 | Oppenheimer | Outperform | Outperform | Maintains |
| 2024-08-22 | Citigroup | Buy | Buy | Maintains |
| 2025-02-24 | Goldman Sachs | Neutral | Neutral | Maintains |
| 2024-10-31 | Needham | Buy | Buy | Maintains |
| 2024-10-04 | Goldman Sachs | Neutral | Initiate | |
| 2024-12-09 | Canaccord Genuity | Buy | Buy | Maintains |
| 2024-10-14 | Truist Securities | Buy | Buy | Maintains |
| 2025-02-21 | Needham | Buy | Buy | Maintains |
| 2025-02-21 | Truist Securities | Buy | Buy | Maintains |
| 2025-02-21 | Wells Fargo | Equal-Weight | Equal-Weight | Maintains |
| 2025-01-13 | Needham | Buy | Buy | Maintains |
| 2025-01-08 | Oppenheimer | Outperform | Outperform | Maintains |
| 2024-12-03 | Wells Fargo | Equal-Weight | Reiterate | |
| 2025-05-02 | Needham | Buy | Buy | Maintains |
| 2025-08-21 | Citigroup | Buy | Buy | Maintains |
| 2025-05-22 | Citigroup | Buy | Buy | Maintains |
| 2025-05-02 | Wells Fargo | Equal-Weight | Overweight | Upgrade |
| 2025-05-02 | Baird | Outperform | Outperform | Maintains |
| 2025-08-28 | Needham | Buy | Buy | Maintains |
| 2025-05-02 | Canaccord Genuity | Buy | Buy | Maintains |
| 2025-08-20 | B of A Securities | Buy | Initiate | |
| 2025-08-01 | Needham | Buy | Buy | Maintains |
| 2025-06-11 | Morgan Stanley | Overweight | Overweight | Maintains |
| 2025-07-15 | Morgan Stanley | Overweight | Overweight | Maintains |
